Nearly £9.5 million has been invested by the European Commission into a new pan- European partnership which will design an advanced diagnostic tool for the detection and control of a potentially life-threatening auto-immune condition, coeliac disease, which is claimed to be the most underdiagnosed common chronic condition in the UK. It is estimated that at least 1 in 100 people in the UK suffer from the condition, leading to serious health problems such as osteoporosis, gastro-intestinal cancer and increased risk of other autoimmune diseases.
Drive to improve diagnosis of coeliac disease
The pan-European collaboration includes a number of UK-based organisations inluding Coeliac UK, the charity. Newcastle University will be responsible for the development and delivery of the development of a sensing technology platform in a screening device and researchers at King’s College London will be leading on the development of an antiglutenin antibody test.
